Healthcare Industry Insights: August 2018

Tuesday 28 August 2018

Kidney Cancer Drugs market is Driven by Changing Lifestyle of the Global Population

The global Kidney Cancer Drugs Market is expected to grow at a healthy rate during the forecast period. Renal Cell Carcinoma (RCC) is one of the most common types of urologic tumors in adults. It accounts for around 2% of all new cases of tumor in humans. However, clinical removal of the cancerous cells is vital for a total cure from the disease. Until last few decades, surgical removal of kidneys. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

Early diagnosis is vital when it comes to treatment of this disease. Various treatment methods such as immune modulation therapy, Vascular Endothelial Growth Factor (VEGF) inhibitors, and cytokine therapy are utilized to cure the tumor. Additionally, variety of drugs are available for the treatment of diseases like kidney cancer when identified at an early stage. Hence, governments and healthcare organizations are engaging in awareness drives for early detection. This factor is anticipated to bode well for market over the forecast period.

Prevalence of RCC is projected to increase in near future owing to factors such as rising obesity and number of smokers and reduced physical activities due to changing lifestyle. Symptoms of renal cancer are similar to several other kidney disorders, which make it difficult to get detected. This factor also reduces survival rate among patients who are mostly diagnosed with RCC during routine checkups for some other medical conditions.

Browse Details of Report @ https://www.hexaresearch.com/research-report/kidney-cancer-drugs-market

The global market is majorly driven by changing lifestyle of the global population. Predominance of lifestyle influenced diseases is one of the major driving factors. Excessive smoking and alcohol consumption lead to chronic diseases including different types of cancer. This factor is expected to fuel the market for kidney cancer medicine in the forthcoming years. Rising geriatric population prone to chronic diseases is projected to propel demand for these medicines in the years to come.

Preference for these drugs over targeted remedies is anticipated to bode well for growth of the global market over the forecast period. Also, availability of a limited number of approved drugs is one of the factors assisting product demand. Kidney cancer medicines are one of the life protracting treatment options available for patients suffering from advanced stage of metastatic tumor. Furthermore, occurrence of this disease is expected to be higher in developed countries compared to developing regions. This factor is expected to impel demand for these medicines from regions like North America and Europe.

However, high price of branded drugs is projected to hinder overall growth over the forecast period. As a result, generic medicine variants are preferred over their branded counterparts. This factor is anticipated to obstruct market development in the forthcoming years.
Primary branded medicines in the global kidney cancer drugs market include Nexavar (Sorafenib), Inlyta (Axitinib), Avastin (Bevacizumab), Votrient (Pazopanib), Afinitor (Everolimus), Sutent (Sunitinib), Torisel (Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). Sutent was one of the highly demanded medicine types in the past. However, drugs like Votrient are also anticipated to witness substantial demand over the forecast period. At present, most potential drugs are in phase II and III clinical trials. Medicines such as Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib are projected to be commercialized and launched in the years to come.

North America accounted for a prominent market share in the past. High prevalence of kidney cancer and other kidney diseases is the primary growth driver. Additionally, U.S. is the largest market for pharmaceuticals. This factor is anticipated to bode well for the growth of the regional demand for kidney cancer drugs. Asia Pacific is estimated to witness significant growth over the forecast period. Lower cost of drug production, high disease prevalence, and rising awareness among healthcare professionals as well as consumers are projected to drive regional growth in the forthcoming years.

The global market is highly consolidated and displays high competition among key participants. Major pharmaceutical giants in the market include Pfizer Inc.; Bayer Pharma AG; GlaxoSmithKline Plc; Hoffman-La Roche; and Novartis AG. Major companies are capitalizing heavily on research and development and adopting strategies like collaborations, new product launches, business expansions, and innovation to uphold their market share.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Global Antibiotics Market Size and Share 2025

The global Antibiotics Market is expected to foresee significant growth over the forecast period. An antibiotic is a type of antimicrobial used to treat a number of bacterial infections and to slow down the growth of such infections in the body. The global market for antibiotics is witnessing immense growth due to rising investments in research and development activities along with continuous product innovations by major companies. Rising awareness regarding the advantages of antibiotics, particularly in Asia Pacific, is also likely to drive the market. Companies that accounted for most of this increase were based in regions including China, Brazil, India, Russia, and South Africa.

Product consumption varies significantly in different countries as per demand. Two classes of antibiotic drugs including carbapenems and polymyxins have shown increase in the consumption in past few years and this trend is expected to continue even during the forecast period. Over the past few years, numerous companies have been engaged in product manufacturing and about 79% of the global demand is covered by aminoglycoside. There are various products present in the market such as tetracyclines, penicillin, erythromycin, chloramphenicol, and streptomycin. Factors such as rising demand for effective drugs and increasing prevalence of infectious diseases, especially in emerging economies including Middle East, Africa, Latin America, and Asia Pacific, are significant growth drivers for the market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/antibiotics-market

This trend is expected to continue over the next few years. Rising geriatric population is also anticipated to contribute toward the market expansion in the years to come. The main challenge this industry is facing is emergence of drug resistant strains. As in the category of drugs, antibacterial drugs have various unique characteristics, which make them little less profitable and therefore less attractive investments. These drugs are prescribed for short course of time, anywhere from 4 days to 2 weeks as compared to the medications for cholesterol and anti-hypertensive patients, which last for several years or decades. Innovation in technical development is the key opportunity for the market. Numerous companies in this field are continually investing to develop new, advanced products in order to increase their product portfolio.

Major attention is focused on research and development of vital but less profitable antibacterial drug for the companies to sell at a premium price. The demand for antibiotics is rising particularly to treat children with pneumonia and sepsis. In most countries, 20% of the product is used by healthcare facilities and hospitals while 80% is used by the community. These are either purchased directly by the consumers or are prescribed by the healthcare providers.

Antibiotics can be classified into seven major classes namely phenicols, quinolones, macrolides, sulfonamides, aminoglycosides, tetracyclines, and beta lactams. Around half of the market share was claimed by beta lactams class in the past. The second largest class was quinolones. However, the market will experience a decline as a result of the adverse effects on sales due to patent expiries. However, fluoroquinolones/quinolones is expected to foresee a significant demand in the market over the forecast period as they are used in treating a large number of infections.

Some of the key companies operating in the global market are Pfizer, Inc.; Abbott Laboratories; GlaxoSmithKline PLC; Daiichii Sankyo Company Limited; Bayer HealthCare Pharmaceuticals LLC; Astellas Pharma, Inc.; Merck & Company, Inc.; Roche Holding AG; Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc.; GlaxoSmithKline Plc; Pliva d.dd; Toyama Chemica Co. Ltd.; Takeda Pharmaceutical Company. Ltd.; Johnson & Johnson; LG Life Sciences Limited; and Eli Lilly and Co. Pfizer Inc. contributed to the largest share in the past, followed by GlaxoSmithKline PLC and Merck & Company, Inc. With very few patented products available at present, generic manufacturers are leading the global market for antibiotics.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry